HCM
SUPN icon

HMS Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

HMS Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-10,100
Closed -$508K – 216
2018
Q3 		$508K Buy
+10,100
New +$499K 0.25% 122

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

HMS Capital Management's SUPN Position: Q4 2018 in Review

HMS Capital Management sold out of Supernus Pharmaceuticals (SUPN) in Q4 2018, closing a stake of 27,171 shares — an estimated $1.37M sold.

HMS Capital Management first reported a position in SUPN in Q3 2018 and held it in 1 quarter. The position peaked at $1.37M in Q3 2018. 274 funds tracked by Wall St. Rank hold SUPN as of Q4 2018.

  • HMS Capital Management reported no remaining Supernus Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • HMS Capital Management sold 27,171 Supernus Pharmaceuticals shares in Q4 2018, an estimated $1.37M.
  • HMS Capital Management first reported a position in Supernus Pharmaceuticals in Q3 2018 and held it in 1 quarter.
  • HMS Capital Management's Supernus Pharmaceuticals position peaked at $1.37M in Q3 2018.
  • 274 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2018.

Based on HMS Capital Management's 13F filing for Q4 2018, filed 14 Jan 2019.